4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia. (PR Newswire FDA.)
4DMedical
ASX: 4DX ~$0.3B (ASX, small-cap) MCAP
4DMedical Limited is an Australian medical device company developing non-contrast ventilation-perfusion (V/Q) lung imaging technology. The company's CT:VQ™ platform enables functional lung assessment without the use of contrast agents or radioactive tracers, addressing a key gap in the diagnosis and monitoring of respiratory disease.
Company Info
Sector:Medical Devices / Diagnostic Imaging
Headquarters:Melbourne, Australia
Founded:2012
Website:4dmedical.com/
Upcoming Milestones & Key Dates
H2 2026
Regulatory / Commercial
Commercial rollout of CT:VQ™ in Australia following TGA approval
Clinical Development Pipeline
CT:VQ™
Target: 4D functional lung imagingRecent News
Leadership Team
Andreas Fouras
Founder and Chief Executive Officer